Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension

Abstract

Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality. Lowering blood pressure (BP) to recommended levels reduces the risk of hypertension-associated cardiovascular events. Despite current treatment options and recommendations, the BP of many patients remains suboptimally controlled. There is a need for more effective management in patients not achieving BP goals on current monotherapy or combination therapy. Regimens combining three or more antihypertensive agents have been shown to increase the proportion of patients achieving BP goals. Recent data suggest that the combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide is a rational treatment option offering safe and effective BP reductions and goal attainment in a greater proportion of patients compared with dual-combination regimens. As the understanding of the importance of BP control grows, treatment options that enable patients to achieve BP goals quickly and safely will become increasingly important in hypertension management.

Keywords::

• amlodipine
• antihypertensive agents
• cardiovascular diseases
• hypertension
• multimodal
• olmesartan
• treatment

Acknowledgements

The author expresses appreciation to the staff of Peloton Advantage, LLC, NJ, USA, for assistance in the preparation of this manuscript.

Financial and competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. The opinions expressed in the current article are those of the author. The author received no honoraria/fee for service or other form of financial support related to the development of this article.

Editorial support for this article was provided by Vrinda Mahajan, PharmD, of Peloton Advantage, LLC.